Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07512583 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Clinical Studies of TQB2930 Injection for the Treatment of Advanced Solid Tumors

Name: Clinical Studies of TQB2930 Injection for the Treatment of Advanced Solid Tumors — clinical trial record (NCT07512583)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 1/2

SponsorChia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

Started2026-05-27

View on ClinicalTrials.gov ↗

Amendment history

2026-06-05

Study Status, Contacts/Locations v1

Recruitment opened

Trial sites expanded: 0 → 3 locations

Start dateestimated 2026-04→confirmed 2026-05-27

2026-04-01

Original filing

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

38 trials monitored

See all monitored trials

This is a multicenter, open-label, multi-cohort phase Ib/II clinical study to evaluate the efficacy and safety of TQB2930 in combination with TQB2102 in patients with HER2-expressing advanced solid tumors.

Trial Details

NCT Number	NCT07512583
Lead Sponsor	Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Conditions	Advanced Solid Tumor
Enrollment	178 participants
Start Date	2026-05-27
Primary Completion	2028-03 (estimated)
Study Completion	2028-12 (estimated)
Updated on ClinicalTrials.gov	2026-06-08